ClinicalTrials.gg

Program

enlonstobart

Also written as “SG001”, “Enlonstobart” and “SYS6041, enlonstobart, bevacizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Stomach Neoplasms · Uterine Cervical Neoplasms · Ovarian Neoplasms, led by 2 companies.

Furthest: phase 3, since Jan 16, 202315 company-led studies, 11 open or runningNext primary completion: Jan 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group1410 open or runningphase 3since Jan 16, 2023Feb 20, 2019Apr 2027phase 2 · NCT06136988
Shanghai Runshi Pharmaceutical Technology11 open or runningphase 2since Nov 9, 2023Nov 9, 2023Jan 30, 2027phase 2 · NCT06132217

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 20, 2019.

  1. Apr 26, 2021Phase 2 study in Uterine Cervical NeoplasmsCSPC Pharmaceutical Group · NCT04886700 · 104 enrolled · China
  2. Jul 16, 2021Phase 2 study in Carcinoma, Ovarian EpithelialCSPC Pharmaceutical Group · NCT04983550 · 126 enrolled
  3. Sep 9, 2021Phase 2 study in Triple Negative Breast NeoplasmsCSPC Pharmaceutical Group · NCT05068141 · 79 enrolled · China
  4. Jan 16, 2023Phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT05715840 · 368 planned
  5. Oct 13, 2023Phase 2 study in Colorectal NeoplasmsCSPC Pharmaceutical Group · NCT06089330 · 102 planned
  6. Nov 8, 2023Phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988 · 129 planned · China
  7. Nov 9, 2023Shanghai Runshi Pharmaceutical Technology's first study: phase 2 study in Advanced Solid TumorNew to Shanghai Runshi Pharmaceutical TechnologyShanghai Runshi Pharmaceutical Technology · NCT06132217 · 168 planned · China
  8. May 12, 2025Phase 2 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT06998771 · 153 planned
  9. Nov 13, 2025Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07251062 · 737 planned
  10. Dec 25, 2025Phase 3 study in HER2-positive Gastric CancerCSPC Pharmaceutical Group · NCT07332533 · 490 planned
  11. May 31, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873 · 500 planned
  12. Jun 21, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07672223 · 586 planned · China
  13. Jul 8, 2026Phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668 · 171 planned · China
  14. Oct 26, 2026Phase 3 study in Esophageal Squamous Cell CarcinomaCSPC Pharmaceutical Group · NCT07924111 · 585 planned

Ahead

  1. Jan 30, 2027Primary completion: phase 2 study in Advanced Solid TumorShanghai Runshi Pharmaceutical Technology · NCT06132217
  2. Apr 2027Primary completion: phase 2 study in Locally Advanced Unresectable Esophageal Squamous CarcinomaCSPC Pharmaceutical Group · NCT06136988
  3. Sep 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT07633873
  4. Apr 30, 2028Primary completion: phase 2 study in Ovarian NeoplasmsCSPC Pharmaceutical Group · NCT07714668

TargetBeta

PDCD1 →read by rule
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34
sasanlimabPfizerphase 34

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07924111Esophageal Squamous Cell Carcinoma3Not yet recruitingCSPC Pharmaceutical GroupDec 30, 2029585
NCT07714668Ovarian Neoplasms · China2RecruitingCSPC Pharmaceutical GroupApr 30, 2028171
NCT07672223Carcinoma, Non-Small-Cell Lung · China3RecruitingCSPC Pharmaceutical GroupSep 30, 2029586
NCT07633873Carcinoma, Non-Small-Cell Lung3Not yet recruitingCSPC Pharmaceutical GroupSep 30, 2027500
NCT07332533HER2-positive Gastric Cancer3Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2032490
NCT07251062Esophageal Squamous Cell Carcinoma3Not yet recruitingCSPC Pharmaceutical GroupDec 30, 2029737
NCT06998771HER2-positive Gastric Cancer2Not yet recruitingCSPC Pharmaceutical GroupJun 30, 2028153
NCT06132217Advanced Solid Tumor · China2Not yet recruitingShanghai Runshi Pharmaceutical TechnologyJan 30, 2027168
NCT06136988Locally Advanced Unresectable Esophageal Squamous Carcinoma · China2Not yet recruitingCSPC Pharmaceutical GroupApr 2027129
NCT06089330Colorectal Neoplasms2Not yet recruitingCSPC Pharmaceutical GroupJul 2024102
NCT05715840Recurrence3Not yet recruitingCSPC Pharmaceutical GroupJul 31, 2024368
NCT05068141Triple Negative Breast Neoplasms · China2UNKNOWNCSPC Pharmaceutical GroupOct 1, 202279
NCT04983550Carcinoma, Ovarian Epithelial2UNKNOWNCSPC Pharmaceutical GroupJan 2023126
NCT04886700Uterine Cervical Neoplasms · China2UNKNOWNCSPC Pharmaceutical GroupDec 31, 2022104
NCT03852823Uterine Cervical Neoplasms · China1UNKNOWNCSPC Pharmaceutical GroupSep 2022192

How it is read

Names in the registry

  • “SG001”, 8 entries
  • “Enlonstobart”, 3 entries
  • “SYS6041, enlonstobart, bevacizumab”, 1 entry
  • “Enlonstobart injection”, 1 entry
  • “SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.